Second generation antibody protects from SARS-CoV-2, its variant and prevents it from mutating to resist therapy

Bellinzona, 25.01.2021 – The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation ‘double antibody’ that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy. Antibody-based immunotherapy was already shown to […]

COVID-19, study shows effectiveness of protective measures in hospitals in Ticino

A study performed in Ticino in Spring 2020, on data of SARS-CoV-2 serological tests run on healthcare workers, shows that COVID-19 antibodies are detectable in up to 10% of the participants. Such a result are comparable with the ones of the Corona Immunitas study conducted on the Ticino population. More importantly, it shows that healthcare […]

New Ebolavirus treatment sees the light thanks to basic research performed in Ticino

While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treatment against another well-known virus, much less widespread but extremely lethal: Ebola. The new drug was made possible thanks to the fundamental work performed at the laboratories of the Institute for Research in […]

New research from Ticino on the antibody response to SARS-CoV-2

After the announcement, in May, of the first results of serological tests carried out on healthcare personnel in Ticino, significant data on the antibody response to SARS-CoV-2 is now available, thanks to the analysis carried out – among others – by the Institute for Research in Biomedicine (IRB, affiliated to USI) and Humabs BioMed (subsidiary […]